In this case study presented at ACTRIMS 2020, researchers reported on data from a patient with Crohn disease and ankylosing spondylitis who developed autoimmune encephalitis while receiving infliximab.
More patients with early relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab experienced confirmed disability improvement than disability worsening.
Patients who have been diagnosed with and treated for multiple sclerosis (MS) have an increased risk for any type of infection, with the highest risk being for renal tract infections.
Home telehealth may be a feasible and safe option for veterans with multiple sclerosis who have difficulty accessing services from the VA or community services.
Using newer disease-modifying therapies for the initial treatment of pediatric multiple sclerosis may be more effective than injectables at controlling disease activity.
The researchers concluded that patients with both MS and depression experience worsening in neurological function, relapses, and lesions activity after 1 year compared with patients without depression.
In this study presented at ACTRIMS Forum 2020, researchers evaluated the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamics of EHP-101, an oral formulation of VCE-004.8.
Pediatric patients with multiple sclerosis (MS) and a high relative abundance of Pasteurellales or Enterobacteriales in their gut microbiota have a lower relapse risk.
